F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

Inclusion Criteria: * male with original diagnosis of prostate carcinoma with prior definitive therapy * suspicion of recurrence (3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir after radiotherapy or cryotherapy and/or PSA rise by greater than 0.2 ng/mL after prostatectomy) * life expectancy of 6 months or more as judged by the investigator * willing and able to undergo all study procedures * informed consent in writing (dated and signed) Exclusion Criteria: * age: less than18 years * contraindications for F-18-Fluorocholine * contraindications for any of the ingredients of F-18-PSMA-1007 * close affiliation with the investigational site; e.g. first-degree relative of the investigator * at the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial * having been previously enrolled in this clinical trial * mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial * being clinically unstable or requiring emergency treatment * being considered a vulnerable person